Answers are grounded in this paper and cite their sources.
Randomized trial shows improved cardiac function in ischemia/reperfusion injury, suggesting a novel drug delivery method.
Single‐dose therapy represents a promising strategy to enhance the convenience and patient compliance in treating myocardial ischemia/reperfusion (MI/R) injury, a long‐lasting therapeutic bottleneck in ischemic heart disease. Nevertheless, existing single‐dose strategies fail to simultaneously address key pathological challenges, including reperfusion‐induced oxidative stress, myocardial hypoxia, and poor drug targeting. Herein, we develop an injectable calcium alginate microgel (termed CaALG‐IMTP@NBP), which is co‐loaded with oxygen‐producing microalgae/perfluorotributylamine (PFTBA) emulsion and DL‐3‐ n ‐butylphthalide (NBP), and is functionalized with an ischemic myocardium‐targeting peptide (IMTP). This composite offers three synergistic benefits: PFTBA oxygen storage enables light‐independent, sustained oxygen release (∼6.5 mg/L); IMTP modification facilitates precise binding to exposed cTnI, extending cardiac drug retention to 3 h and increasing local NBP concentration by 2.1‐fold; and the CaALG matrix provides pH‐responsive, sustained release of loaded NBP, which activates the Nrf2/HO‐1 pathway to suppress oxidative stress and reduce cardiomyocyte apoptosis by 57%. In a mouse MI/R model, a single pre‐ischemic injection of CaALG‐IMTP@NBP significantly improved cardiac function (32% increase in LVEF), reduced infarct size by 45%, and lowered serum biomarkers, outperforming daily oral NBP. This biocompatible and biodegradable platform establishes a novel strategy for single‐dose MI/R therapy and holds immense potential for clinical translation.
No takes yet. Share an insight, caveat, or question.
Liao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: